Gene therapy using CRISPR/Cas9 is not accessible and equitable. That is due to complicated and costly ex vivo therapeutical process caused by the lack of versatile delivery platform able to be used systemically in vivo. In this project I will develop liposome-based delivery platform consisting of several types of lipids and pH sensitive structure enabling controlled release of CRISPR/Cas9 into cytoplasm. This liposome will be tested for gene knock-out. The proposed platform can be easily functionalized for cell-specific delivery or theranostics

CEITEC VUT-J-22-8056

Czech

Ressnerová Alžběta, M.Sc., MSc - principal person responsible
Heger Zbyněk, doc. Mgr., Ph.D. - fellow researcher

Central European Institute of Technology BUT
- responsible department (11.2.2022 - 3.3.2022)
Smart Nanodevices
- responsible department (3.3.2022 - not assigned)
Smart Nanodevices
- internal (1.1.2022 - 31.12.2022)
Central European Institute of Technology BUT
- beneficiary (1.1.2022 - 31.12.2022)

Responsibility: Ressnerová Alžběta, M.Sc., MSc